期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (2)
BackgroundMedications with anticholinergic and/or sedative properties are commonly used in the management of psychiatric illnesses. The burden of anti......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (2)
BackgroundPatients with chronic postsurgical pain are commonly prescribed opioids chronically because of refractory pain although chronic opioid use c......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (4)
BackgroundSeveral oral drugs are recommended to be taken with large amounts of water for reasons such as peptic ulcer prophylaxis. On the other hand, ......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (4)
Introduction Numerous investigations on herbal medicine that have been undertaken in the past several years demonstrate the general acceptance of its ......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (3)
Background Brexanolone is currently the only medication approved by the US FDA for the treatment of postpartum depression (PPD) in patients >= 15 y......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (2)
BackgroundUse of real-world evidence (RWE) has been limited for evaluating effectiveness because of the lack of confidence in its reliability. Examini......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; ()
ObjectiveDrug non-adherence in primary preventive cardiovascular therapy is one of the most important modifiable drivers of cardiovascular events. The......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (1)
Background The efficacy and safety of golimumab in elderly patients with renal dysfunction are not well evaluated due to the exclusion criteria of cli......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (1)
Background and Objectives Elderly individuals are more vulnerable to potential drug-drug interactions (pDDIs) as age-related physiological changes, po......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; ()
Background Ailments such as diarrhoea and antibiotic-associated gut symptoms are generally self-managed using probiotics. Real-world data on reasons b......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (1)
Presently, Gulf Cooperation Council countries are lagging in the generation of real-world data and use of real-world evidence for patient-centered car......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (3)
BackgroundThere is limited real-world evidence regarding the safety of ramucirumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC).O......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; ()
BackgroundIsotretinoin, indicated for severe acne, is a potent teratogen and therefore contraindicated in pregnancy. Thus, the pregnancy prevention pr......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (4)
Background Safe and appropriate use of medicines is essential to improve health outcomes in cirrhosis. However, little is known about the number and t......
期刊： DRUGS-REAL WORLD OUTCOMES, 2023; 10 (1)
Background The multikinase inhibitors (MKIs) sorafenib, lenvatinib, and vandetanib are approved for advanced thyroid cancer (TC) in Japan. How sequent......
